AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04171375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trans-spinal Electrical Stimulation (tsES)
Description: The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
Study NCT04265846 — intervention group
Intervention type: DEVICE
Intervention: bifocal IOL
Description: The patients will undergo bilateral phacoemulsification and bifocal IOLs implantation.
Study NCT04265846 — intervention group
Intervention type: DEVICE
Intervention: mix bifocal IOL
Description: The patients will undergo phacoemulsification and mix different bifocal IOLs implantation bilaterally.
Study NCT04265846 — intervention group
Intervention type: DEVICE
Intervention: trifocal IOL
Description: The patients will undergo bilateral phacoemulsification and trifocal IOLs implantation.
Study NCT04265846 — intervention group
Intervention type: DEVICE
Intervention: EDOF IOL
Description: The patients will undergo bilateral phacoemulsification and EDOF IOLs implantation.
Study NCT04265846 — intervention group
Intervention type: DEVICE
Intervention: different IOLs
Description: The patients will undergo phacoemulsification and different IOLs implantation bilaterally.
Study NCT04265846 — intervention group
Intervention type: DEVICE
Intervention: monofocal IOL
Description: The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with monovision designed.
Study NCT04265846 — intervention group
Intervention type: DEVICE
Intervention: monofocal IOL
Description: The patients will undergo bilateral phacoemulsification and monofocal IOLs implantation with emmetropia designed.
Study NCT01981915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPPB
Description: Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
Study NCT01981915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIAM
Description: Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
Study NCT04551937 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Free 1% Milk
Description: 8 oz of study beverage daily
Study NCT04551937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactose Free 1% Milk + 10 g prebiotic
Description: 8 oz of study beverage supplemented with 5 grams of fructooligosaccharide and 5 grams of galactooligosaccharide
Study NCT04027400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: computer-assisted rehabilitation
Description: Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
Study NCT04027400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: computer-assisted rehabilitation
Description: Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
Study NCT04599777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with sorafenib and tislelizumab
Description: Sorafenib (400mg P.O. Bid) and tislelizumab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated. Treatment of tislelizumab will last up to 24 months. Patients will be allowed to have sorafenib or tislelizumab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study NCT04193007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: molecular targeted therapies
Description: if EGFR mutation is positive, (gefitinib, ecotinib, erlotinib）or ALK/ROS-1 positive（Crizotinib）
Study NCT04193007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain Radiotherapy
Description: SRS was used for 1-3 intracranial lesions, and simultaneous modulated accelerated radiation therapy for Brain(SMART-Brain)was used for more than 3 intracranial lesions
Study NCT03724071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG6002
Description: Phase I, Arm A: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU; Phase I, Arm B: Dose escalation from 1 x 10E9 PFU to 1 x 10E10 PFU; Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15 (Phase I, Arm A) or on Days 1, 3 and 5 (Phase I, Arm B). Three intravenous infusions at the Dose Recommended for Phase 2 (RP2D) in Phase IIa.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake.
Study NCT03724071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine (5-FC, Ancotil)
Description: Administered orally at a dose of 200 mg/kg/day for a total of 10 days (Phase I, Arm B) or 16 days (Phase I, Arm A).~An extension of the cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms.
Study NCT01365260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MM-II
Description: Single intraarticular (knee) injection of MM-II
Study NCT01365260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DurolaneTM
Description: Single intraarticular (knee) injection of DurolaneTM
Study NCT03373097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2-CART01
Description: Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Study NCT04179734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Description: Melanocortin-4 receptor agonist subcutaneous injection.
Study NCT04179734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bremelanotide
Description: Melanocortin-4 receptor agonist subcutaneous injection.
Study NCT04179734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaenous injection.
Study NCT04179734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaenous injection.
Study NCT04027114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized behavioural physical activity intervention
Description: • The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
Study NCT02966509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPAC
Description: Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
Study NCT01389167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivitrol
Description: An extended release naltrexone formulation for intramuscular injection
Study NCT01389167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (oral)
Description: Naltrexone 50 mg pills, daily
Study NCT01389167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BDRC
Description: Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
Study NCT01389167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
Study NCT02258789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-method
Description: Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
Study NCT01086462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2239633
Description: 100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633
Study NCT02644564 — intervention group
Intervention type: OTHER
Intervention: Ultrasonography
Description: One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
Study NCT02263079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
Study NCT02263079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
Study NCT02263079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2A
Description: Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
Study NCT00199550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Transurethral Resection of the Prostate
Description: Bipolar TURP
Study NCT00199550 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar Transurethral Resection of the Prostate
Description: Monopolar TURP
Study NCT02965521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website and text messages
Description: Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
Study NCT00019708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT01199042 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BiPAP autoSV Advanced
Description: The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
Study NCT02053168 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Resorbable Mesh
Description: Phasix Mesh
Study NCT02905370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Multi-Component (PMC)
Description: Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program.
Study NCT01194856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Description: 300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
Study NCT01194856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Maintain dosage - 600 mg orally QHS for 96 weeks
Study NCT01491607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax
Description: BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
Study NCT02905370 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Participants in the Enhanced Usual Care group will receive standardized physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education.~Name of Participant Arm updated to Enhanced Usual Care from Usual Care effective 8/16/18 to distinguish from Passive Comparator True Usual Care group.
Study NCT01114503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - low dose
Description: 8 day dose rising intravenous infusions of a low dose of otelixizumab
Study NCT01114503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - medium low dose
Description: 8 day dose rising intravenous infusions of a medium low dose of otelixizumab
Study NCT01114503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - medium high dose
Description: 8 day dose rising intravenous infusions of a medium high dose of otelixizumab
Study NCT01114503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab - high dose
Description: 8 day dose rising intravenous infusions of a high dose of otelixizumab
Study NCT01114503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Description: 8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
Study NCT01114503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
Study NCT01602770 — intervention group
Intervention type: DRUG
Intervention: EV/DNG (Qlaira, BAY86-5027)
Description: Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
Study NCT01748175 — intervention group
Intervention type: DRUG
Intervention: Triamcinolone Acetonide
Description: Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
Study NCT03446222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
Study NCT03446222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-maze surgical procedure
Description: Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
Study NCT00983177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg twice daily for 4 months
Study NCT00983177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose
Description: lactose capsules twice daily
Study NCT01234974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
Study NCT01234974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: given as an oral tablet every day on days 1-28, 10 mg per day
Study NCT04539340 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GNR-055
Description: Single intravenous administration
Study NCT00360594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 3 pills (666 mg) for 1998mg/day
Study NCT00360594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 pills (666mg) for 1998mg/day
Study NCT02318667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
Study NCT02244216 — intervention group
Intervention type: DRUG
Intervention: Berotec® N 100 µg Metered-dose Inhaler
Study NCT02466711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relamorelin
Description: Double blind RM-131 will be delivered three times by injection during the course of the study
Study NCT02466711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blind Placebo will be delivered three times by injection during the course of the study
Study NCT01441830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
Study NCT01441830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Radial extracorporeal shock wave therapy
Description: The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
Study NCT02347098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intensive LDL-lowering therapy
Description: The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
Study NCT02347098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Study NCT02347098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard statin monotherapy
Description: The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
Study NCT02424942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular
Study NCT02424942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ389988
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular
Study NCT00128856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00128856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycine
Study NCT00128856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02861209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a care pathway
Description: The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.